The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival.
M. Toulmonde
No relevant relationships to disclose
A. Italiano
No relevant relationships to disclose
N. Penel
No relevant relationships to disclose
A. Cioffi
No relevant relationships to disclose
A. Le Cesne
No relevant relationships to disclose
N. Isambert
No relevant relationships to disclose
E. Bompas
No relevant relationships to disclose
F. Duffaud
No relevant relationships to disclose
A. Patrikidou
No relevant relationships to disclose
R. G. Maki
No relevant relationships to disclose
J. Coindre
No relevant relationships to disclose
J. Blay
Consultant or Advisory Role - GlaxoSmithKline; ImClone Systems; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
B. Bui Nguyen
No relevant relationships to disclose